VNRX (VolitionRx Ltd) Cumulative Company Assets
This daily price chart on GURU.Markets shows that the total asset value of VolitionRx Limited (VNRX) is 8.50. While the business specializes in cancer detection, it faces slow test adoption and costly research. Financial stability is constrained by volatile cash flows and a reliance on grants. The lack of mature products leaves the company vulnerable, forcing it to depend on external capital to drive innovation.
%20Company%20Total%20Assets&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261030&filename=GURU_Markets_-_VNRX_-_VolitionRx-Limited_-_Company-Total-Assets "VolitionRx (VNRX) - Company Total Assets from 07/04/2022 to 10/30/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for volition.com (VNRX)
Investors assess the business's margin of safety through the combination of equity and debt capital, which in this calculation is reverse-engineered from the return on assets (ROA) to filter out market noise. The trend in total assets for VolitionRx Limited (VNRX) reflects the resource base for the commercialization of the Nu.Q platform and expansion into veterinary diagnostics, determining the scaling potential of this high-tech asset.